<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961764</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-US-ID-0476</org_study_id>
    <nct_id>NCT02961764</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</brief_title>
  <official_title>A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new critical pathway (use of guideline-based patient
      identification criteria and for those who meet these criteria, use of dalbavancin) for the
      treatment of ABSSSI compared to usual care.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Actual">March 29, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Admission Rate at Initial Episode of Care</measure>
    <time_frame>44 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Total Admitted Hospital Days</measure>
    <time_frame>44 Days</time_frame>
    <description>Number of days during the initial hospitalization (for those initially hospitalized) and all other hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care</measure>
    <time_frame>Initial Care: 14 Days</time_frame>
    <description>Time spent in ED in hours from triage to release (either admitted to the hospital, admitted to observation, or released to home)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Major Surgical Interventions That Required Operating Room Time</measure>
    <time_frame>44 Days</time_frame>
    <description>Number of all major surgical interventions unexpected or expected that required operating room time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infection-related Total Admitted Hospital Days</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Hospitalizations</measure>
    <time_frame>44 Days</time_frame>
    <description>Number of days of hospitalization during the initial hospitalization (for those initially hospitalized) and all other infection-related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Hospitalizations During Initial Care and Follow-up That Resulted in Admission to Intensive Care Unit</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED</measure>
    <time_frame>Follow-up: 30 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Emergency Department (ED) Visits</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Outpatient Healthcare Visits</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Infection-related Healthcare Visits Due to PICC Line or Central Line Used to Administer Antibiotic Therapy</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>44 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Overall Health</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Wait in Emergency Room</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Hospitalization</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Satisfaction With Hospital Stay</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Received IV Antibiotic Therapy for Skin Infections</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV</measure>
    <time_frame>14 Days</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: IV Therapy Hindering Normal Activities of Daily Living</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Concerned About Receiving Your IV Therapy</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV</measure>
    <time_frame>Day 14</time_frame>
    <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Time to Travel to Appointments to Receive IV</measure>
    <time_frame>14 days</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Average Time to be Seen by a Healthcare Provider</measure>
    <time_frame>14 days</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Healthcare Setting Preferred if Treated Again for a Skin Infection With IV</measure>
    <time_frame>14 Days</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care</measure>
    <time_frame>14 Days</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Regimen Preferred if Treated Again for a Similar Skin Infection With IV</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Time Willing to Spend Receiving Each IV</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Care: Find Value in a Physician</measure>
    <time_frame>Day 14</time_frame>
    <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire</measure>
    <time_frame>Day 14</time_frame>
    <description>Number of days with lost/reduced productivity during follow-up, as measured with Work Productivity and Activity Impairment (WPAI) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire</measure>
    <time_frame>Day 14</time_frame>
    <description>The SF-12 yields a physical and a mental health component summary score (referred to as physical component summary score [PCS] and mental component summary score [MCS]). The PCS and MCS follow a t-score distribution, i.e. mean of 50 and standard deviation of 10 in the general US population, meaning all scores above or below 50 are above and below the average, respectively, in the US general population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Critical Pathway</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin</intervention_name>
    <description>Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.</description>
    <arm_group_label>New Critical Pathway</arm_group_label>
    <other_name>DalvanceÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presents to the Emergency Department (ED) and meets the clinical definition for Acute
             Bacterial Skin and Skin Structure Infections (ABSSSI)

          -  Known or suspected gram-positive infection.

        Exclusion Criteria:

          -  Known or suspected gram-negative infections, anaerobic infections, or fungemia

          -  Known or suspected infections that are severe, life threatening or are not included in
             the ABSSSI Food and Drug Administration (FDA) guidance

          -  Injection drug users with a fever

          -  Severe neurological disorder leading to immobility or confined to a wheelchair

          -  Bilateral Lower extremity involvement of the suspected infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Gillard</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View-UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Monroe Regional Hospital</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://allerganclinicaltrials.com</url>
    <description>More Information</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <results_first_submitted>March 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2020</results_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Pathways</keyword>
  <keyword>Health Facilities</keyword>
  <keyword>Clinical Protocols</keyword>
  <keyword>Patient Satisfaction</keyword>
  <keyword>Absenteeism</keyword>
  <keyword>Anti-Bacterial Agents</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Economics, Medical</keyword>
  <keyword>Health Resources</keyword>
  <keyword>Health resource utilization</keyword>
  <keyword>Acute bacterial skin and skin structure infection (ABSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02961764/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02961764/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
        </group>
        <group group_id="P2">
          <title>New Critical Pathway</title>
          <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.</population>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
        </group>
        <group group_id="B2">
          <title>New Critical Pathway</title>
          <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="309"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;20 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20-29 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30-39 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>40-49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>50-59 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>60-69 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>70-79 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>80-89 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>90-98 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patient chose not to answer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Admission Rate at Initial Episode of Care</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Admission Rate at Initial Episode of Care</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.289</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.532</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Admitted Hospital Days</title>
        <description>Number of days during the initial hospitalization (for those initially hospitalized) and all other hospitalizations</description>
        <time_frame>44 Days</time_frame>
        <population>FAS population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Admitted Hospital Days</title>
          <description>Number of days during the initial hospitalization (for those initially hospitalized) and all other hospitalizations</description>
          <population>FAS population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.74"/>
                    <measurement group_id="O2" value="1.2" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care</title>
        <description>Time spent in ED in hours from triage to release (either admitted to the hospital, admitted to observation, or released to home)</description>
        <time_frame>Initial Care: 14 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Length of Stay in Emergency Department (ED) During the Initial Episode of Care</title>
          <description>Time spent in ED in hours from triage to release (either admitted to the hospital, admitted to observation, or released to home)</description>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="9.09"/>
                    <measurement group_id="O2" value="6.1" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Major Surgical Interventions That Required Operating Room Time</title>
        <description>Number of all major surgical interventions unexpected or expected that required operating room time</description>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Major Surgical Interventions That Required Operating Room Time</title>
          <description>Number of all major surgical interventions unexpected or expected that required operating room time</description>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No Surgeries</title>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any Surgeries</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infection-related Total Admitted Hospital Days</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infection-related Total Admitted Hospital Days</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.06"/>
                    <measurement group_id="O2" value="1.0" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Hospitalizations</title>
        <description>Number of days of hospitalization during the initial hospitalization (for those initially hospitalized) and all other infection-related hospitalizations</description>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Hospitalizations</title>
          <description>Number of days of hospitalization during the initial hospitalization (for those initially hospitalized) and all other infection-related hospitalizations</description>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Any</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Hospitalizations During Initial Care and Follow-up That Resulted in Admission to Intensive Care Unit</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Hospitalizations During Initial Care and Follow-up That Resulted in Admission to Intensive Care Unit</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Admission to ICU</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED</title>
        <time_frame>Follow-up: 30 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Cause Hospitalizations in the 30 Days Post Discharge From the Hospital or Release From the ED</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Emergency Department (ED) Visits</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Emergency Department (ED) Visits</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Outpatient Healthcare Visits</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Outpatient Healthcare Visits</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of a Peripherally-Inserted Central Catheter (PICC) Line or Central Line to Administer Antibiotic Therapy</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peripheral IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PICC line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Infection-related Healthcare Visits Due to PICC Line or Central Line Used to Administer Antibiotic Therapy</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infection-related Healthcare Visits Due to PICC Line or Central Line Used to Administer Antibiotic Therapy</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion. Patients who discontinued prior to day 14 of the study were excluded from the Follow-up and Entire Study Duration analyses due to missing data for 15-44 day period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 occurence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <time_frame>44 Days</time_frame>
        <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <population>Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Overall Health</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Overall Health</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Excellent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Wait in Emergency Room</title>
        <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Wait in Emergency Room</title>
          <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.63"/>
                    <measurement group_id="O2" value="8.3" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Hospitalization</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Hospitalization</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Satisfaction With Hospital Stay</title>
        <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. 63 and 27 patients had a hospital stay in the usual care group and new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Satisfaction With Hospital Stay</title>
          <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. 63 and 27 patients had a hospital stay in the usual care group and new critical pathway group, respectively.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="2.19"/>
                    <measurement group_id="O2" value="8.0" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Factors for Dissatisfaction With Your Hospital Stay</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospital stay interfered with work/school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stay got in way of daily normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stay got in the way of providing care to others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay was expensive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not provide adequate monitoring by providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not provide well trained healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay made me feel worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay made me feel concerned</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay was uncomfortable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital stay disrupted my sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I was not dissatisfied with my hospital stay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Received IV Antibiotic Therapy for Skin Infections</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Received IV Antibiotic Therapy for Skin Infections</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy</title>
        <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
        <time_frame>Day 14</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 119 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Satisfaction With Receiving IV Antibiotic Therapy</title>
          <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 119 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="2.16"/>
                    <measurement group_id="O2" value="9.0" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Factors Contributing to Satisfaction With Receiving IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Allowed me to return to work/school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allowed me to return to daily normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allowed me to return to providing care to others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy was affordable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered at appointments that I could schedule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered quickly once arrived at appt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered at setting that had convenient hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ensured regular monitoring by healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered by skilled healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy made me feel better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allowed to receive care for skin infection at home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenient to administer by self/caregiver at home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfied with receiving IV antibiotic therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>14 Days</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Factors Contributing to Dissatisfaction With Receiving IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Got in the way of work/school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Got in way of performing daily normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Got in the way of providing care to others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy was expensive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required me to make appointments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered at healthcare setting w/limited hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required traveling to and from appointments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required to wait to be seen by provider</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy took too long to administer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required having a PICC or central line inserted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caused an IV site infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy made me feel worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not adequately monitored by healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not administered by skilled healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV antibiotic therapy made me feel concerned</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required a nurse/healthcare worker coming to home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required administration to self/caregiver at home</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not dissatisfied w/receiving IV antibiotic therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: IV Therapy Hindering Normal Activities of Daily Living</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 87 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: IV Therapy Hindering Normal Activities of Daily Living</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 87 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A little of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Most of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>All of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Concerned About Receiving Your IV Therapy</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 87 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Concerned About Receiving Your IV Therapy</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 87 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A little of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Most of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>All of the time</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day</title>
        <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
        <time_frame>Day 14</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 85 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Satisfied With the Number of IV Infusions Received Per Day</title>
          <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 85 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.36"/>
                    <measurement group_id="O2" value="9.0" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV</title>
        <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
        <time_frame>Day 14</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 85 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Satisfaction With the Average Time to Administer Each IV</title>
          <description>Patients rated their satisfaction on a 10-point scale, where 0 was the worst experience possible and 10 the best experience possible.</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 85 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.87"/>
                    <measurement group_id="O2" value="8.8" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Time to Travel to Appointments to Receive IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>14 days</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Time to Travel to Appointments to Receive IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than 15 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16 - 30 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>31 - 60 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>61 - 90 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than 90 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>I did not need to travel to my appointments</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>I don't remember</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Average Time to be Seen by a Healthcare Provider</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>14 days</time_frame>
        <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Average Time to be Seen by a Healthcare Provider</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>119 &amp; 124 patients provided any survey data in the usual care group &amp; new critical pathway group; 87 &amp; 119 patients received IV antibiotic therapy in the usual care group &amp; new critical pathway group; 86 and 118 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than 15 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16 - 30 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>31 - 60 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>61 - 90 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than 90 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>I did not need to wait for my appointments</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>I don't remember</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Healthcare Setting Preferred if Treated Again for a Skin Infection With IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>14 Days</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 116 and 123 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Healthcare Setting Preferred if Treated Again for a Skin Infection With IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 116 and 123 patients answered this question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Overnight hospital stay for one or more nights</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Outpatient care: Brief hospital visit w/no stay</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>14 Days</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Factors Contributing to Preference for Outpatient Care</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group, respectively. Patients may have checked multiple responses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>To avoid hospital stay for 1 or more nights</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>To allow me to return to work/school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>To return to performing daily normal living</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>To allow me to return to providing care to others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care would be more affordable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient care would be more convenient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>To ensure monitoring by healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Administered by skilled healthcare providers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I would not prefer outpatient care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Regimen Preferred if Treated Again for a Similar Skin Infection With IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 121 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Regimen Preferred if Treated Again for a Similar Skin Infection With IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 121 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Regimen 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Regimen 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Regimen 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Time Willing to Spend Receiving Each IV</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 123 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Time Willing to Spend Receiving Each IV</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 117 and 123 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>About 30 minutes or less</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About 1 hour</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About 1.5 to 2 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About 3 hours or longer</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Care: Find Value in a Physician</title>
        <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 115 and 123 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Care: Find Value in a Physician</title>
          <description>Patient satisfaction with care as assessed through the ABSSSI Patient Satisfaction Survey (patient reported).</description>
          <population>FAS population. 119 and 124 patients provided any survey data in the usual care group and the new critical pathway group; 115 and 123 patients answered this survey question in the usual care group &amp; new critical pathway group, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Definitely not</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probably not</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Probably so</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Definitely so</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire</title>
        <description>Number of days with lost/reduced productivity during follow-up, as measured with Work Productivity and Activity Impairment (WPAI) Questionnaire</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 123 patients provided any survey data in the usual care group and the new critical pathway group; 53 and 48 patients completed all survey questions in the usual care group and new critical pathway group, respectively. 61 and 56 were employed.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Work and Productivity Loss as Assessed Through the Work Productivity and Activity Impairment Questionnaire</title>
          <description>Number of days with lost/reduced productivity during follow-up, as measured with Work Productivity and Activity Impairment (WPAI) Questionnaire</description>
          <population>FAS population. 119 and 123 patients provided any survey data in the usual care group and the new critical pathway group; 53 and 48 patients completed all survey questions in the usual care group and new critical pathway group, respectively. 61 and 56 were employed.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="31.96"/>
                    <measurement group_id="O2" value="18.9" spread="33.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impairment while working</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="24.14"/>
                    <measurement group_id="O2" value="10.8" spread="22.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall work impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="29.04"/>
                    <measurement group_id="O2" value="16.4" spread="26.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="34.06"/>
                    <measurement group_id="O2" value="15.9" spread="28.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire</title>
        <description>The SF-12 yields a physical and a mental health component summary score (referred to as physical component summary score [PCS] and mental component summary score [MCS]). The PCS and MCS follow a t-score distribution, i.e. mean of 50 and standard deviation of 10 in the general US population, meaning all scores above or below 50 are above and below the average, respectively, in the US general population.</description>
        <time_frame>Day 14</time_frame>
        <population>FAS population. 119 and 122 patients provided any and all survey data in the usual care group and the new critical pathway group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
          </group>
          <group group_id="O2">
            <title>New Critical Pathway</title>
            <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Health-related Quality of Life (HRQoL) Assessed by the Short Form 12 (SF-12) 12-Item Patient Questionnaire</title>
          <description>The SF-12 yields a physical and a mental health component summary score (referred to as physical component summary score [PCS] and mental component summary score [MCS]). The PCS and MCS follow a t-score distribution, i.e. mean of 50 and standard deviation of 10 in the general US population, meaning all scores above or below 50 are above and below the average, respectively, in the US general population.</description>
          <population>FAS population. 119 and 122 patients provided any and all survey data in the usual care group and the new critical pathway group, respectively.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental Health Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="10.36"/>
                    <measurement group_id="O2" value="52.6" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" spread="10.36"/>
                    <measurement group_id="O2" value="47.8" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 44 days. Initial care is the date of enrollment to 10-14 days and follow-up is 30 days after initial care.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.</description>
        </group>
        <group group_id="E2">
          <title>New Critical Pathway</title>
          <description>The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>TREATMENT FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>SKIN BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CULTURE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>HIDRADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

